BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 56 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)		 PLK2 [1]
(Cell-free assay)		 PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 M37r[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnTd|RvUUN3ME2wMlAxPzd4IN88US=> Ml7yV2FPT0WU
ACN NX3JOWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDbWlEPTB;MD6wNFg1OyEQvF2= MlftV2FPT0WU
TE-8 NHXIVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPlTWM2OD1yLkCwPVQyKM7:TR?= M4H3UnNCVkeHUh?=
LC-2-ad M1XJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\tTWM2OD1yLkCxNFk{KM7:TR?= MU\TRW5ITVJ?
ALL-PO NYTGN2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEGzJO69VQ>? M1W1bHNCVkeHUh?=
EW-16 M1TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEGzN|Yh|ryP NF3wdYJUSU6JRWK=
KM12 M2\IW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETjXFFKSzVyPUCuNFE{PDhizszN Moq2V2FPT0WU
GI-1 NHnDTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LCcWlEPTB;MD6wNVM5OyEQvF2= NH\IZnRUSU6JRWK=
LS-411N NFLxR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZTWM2OD1yLkCxOFA4KM7:TR?= M4nUTXNCVkeHUh?=
ES8 NGPEXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXpfWRKSzVyPUCuNFE1QTRizszN NUPUZlh1W0GQR1XS
SNU-C2B NETJRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17SSmlEPTB;MD6wNVUzPiEQvF2= NHPGRoFUSU6JRWK=
CESS NEjrUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5UmFKSzVyPUCuNFE3ODJizszN M{KzNnNCVkeHUh?=
697 M1z0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S1VWlEPTB;MD6wNVY3QCEQvF2= MWnTRW5ITVJ?
NCI-H1963 M1PCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLzTWM2OD1yLkCxOlc{KM7:TR?= MUTTRW5ITVJ?
IA-LM NWryU4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDVJlKSzVyPUCuNFE3QDhizszN NHzERXBUSU6JRWK=
SW954 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXLTWM2OD1yLkCxO|A2KM7:TR?= MU\TRW5ITVJ?
RL95-2 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VUGlEPTB;MD6wNVc{QCEQvF2= MXPTRW5ITVJ?
LXF-289 M{O3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rxc2lEPTB;MD6wNVc4KM7:TR?= M2jQW3NCVkeHUh?=
OCUB-M MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjNdYxKSzVyPUCuNFE5OjZizszN NVqxT2tqW0GQR1XS
RKO NULPN3RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5TWM2OD1yLkCxPVg4KM7:TR?= NXfTc2tiW0GQR1XS
LOUCY MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fJZmlEPTB;MD6wNlA2KM7:TR?= MYrTRW5ITVJ?
NOS-1 NIDEOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faRWlEPTB;MD6wNlA6OyEQvF2= M4DTN3NCVkeHUh?=
A4-Fuk MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{iy[2lEPTB;MD6wNlIyQCEQvF2= MkL6V2FPT0WU
A388 M1rHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P5TmlEPTB;MD6wNlIzPyEQvF2= M2S3VHNCVkeHUh?=
TE-9 NFjp[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFywcINKSzVyPUCuNFIzPjFizszN MVnTRW5ITVJ?
KURAMOCHI M1nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PpNmlEPTB;MD6wNlI5PSEQvF2= NIe0fXNUSU6JRWK=
KALS-1 NFnPfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW1TWM2OD1yLkCyN|M5KM7:TR?= NF3MflZUSU6JRWK=
HOP-62 NXHE[GhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHKNnA{UUN3ME2wMlAzPDJizszN NI[wNYNUSU6JRWK=
RPMI-8402 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0TWM2OD1yLkCyOVA5KM7:TR?= MljrV2FPT0WU
TE-1 NYWzemxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fjRmlEPTB;MD6wNlUyOiEQvF2= MXfTRW5ITVJ?
CCRF-CEM MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEK1OFMh|ryP MX7TRW5ITVJ?
HUTU-80 NFjrWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL2WYZ2UUN3ME2wMlAzPjJ2IN88US=> MomzV2FPT0WU
NCI-H1648 NWXXVIRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjTWM2OD1yLkCyOlQ4KM7:TR?= NVLze21OW0GQR1XS
HCE-4 NHuxOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHLTWM2OD1yLkCyOlgzKM7:TR?= M2HqVXNCVkeHUh?=
ETK-1 NHqybnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13HcmlEPTB;MD6wNlc{PiEQvF2= NVrrO21GW0GQR1XS
TE-15 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWntVFBkUUN3ME2wMlAzPzN6IN88US=> NUD3NmtUW0GQR1XS
BE-13 NEe0TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEK3OEDPxE1? MkfDV2FPT0WU
KE-37 NGXJZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXGTWM2OD1yLkCyO|QyKM7:TR?= MkixV2FPT0WU
NCI-H1355 NEPNbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEK3PFMh|ryP MorDV2FPT0WU
TE-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XqNWlEPTB;MD6wNlgxQSEQvF2= NEfVNGNUSU6JRWK=
BL-70 M1ntbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnGdHdKSzVyPUCuNFI5PTdizszN MX\TRW5ITVJ?
ES6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHMOGxKSzVyPUCuNFI5QDFizszN MnzOV2FPT0WU
GT3TKB NWi3PWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X6XWlEPTB;MD6wNlk2OyEQvF2= M3n0fHNCVkeHUh?=
LB647-SCLC M4PGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3lUnZmUUN3ME2wMlA{OTl3IN88US=> NIXvXWNUSU6JRWK=
NB13 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33zRWlEPTB;MD6wN|MyPiEQvF2= NIDpPHFUSU6JRWK=
ST486 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEOzN|ch|ryP NHnT[Y9USU6JRWK=
NCI-H82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvPTWM2OD1yLkCzN|Q{KM7:TR?= NV31[3RzW0GQR1XS
NTERA-S-cl-D1 M1eyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW2XllKSzVyPUCuNFM{QTlizszN MkPpV2FPT0WU
ES4 NWm3S3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX6dJZNUUN3ME2wMlA{PDZ|IN88US=> MXfTRW5ITVJ?
SK-NEP-1 NUfSeplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq2TpRKSzVyPUCuNFM1QTlizszN MnfRV2FPT0WU
Becker NWj6T|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLLTWM2OD1yLkCzOVU2KM7:TR?= MlTrV2FPT0WU
A101D NWjLTFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEO3OFgh|ryP Ml\5V2FPT0WU
SK-UT-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfie2hKSzVyPUCuNFM4PzRizszN NUP3eFN{W0GQR1XS
SW982 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEO3PUDPxE1? NWLQ[XFTW0GQR1XS
TE-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXPTplKSzVyPUCuNFQxPDZizszN MVXTRW5ITVJ?
OVCAR-4 NXHmUW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD1yLkC0NFU6KM7:TR?= Mni1V2FPT0WU
KP-N-YS NUS1[3JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qxWmlEPTB;MD6wOFA5PSEQvF2= M2DwRnNCVkeHUh?=
BL-41 NFvlSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLxem1wUUN3ME2wMlA1OTJ3IN88US=> MnPhV2FPT0WU
MZ1-PC NVrnd|ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nOfWlEPTB;MD6wOFEzPyEQvF2= NUnMRZN2W0GQR1XS
PF-382 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj5TWM2OD1yLkC0NVk5KM7:TR?= M4TBN3NCVkeHUh?=
MOLT-13 NIjwZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMESyN|gh|ryP M2H2UXNCVkeHUh?=
HCC1599 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfMR2pKSzVyPUCuNFQzPThizszN MVPTRW5ITVJ?
IST-MEL1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOxTo9vUUN3ME2wMlA1PDR{IN88US=> MnjmV2FPT0WU
LU-139 NIC1eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDcGlEPTB;MD6wOFQ1OiEQvF2= NVmyZYZkW0GQR1XS
MS-1 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMES3NFEh|ryP NHTlUphUSU6JRWK=
MFH-ino MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fSfmlEPTB;MD6wOVAxOyEQvF2= NHW5TIFUSU6JRWK=
IMR-5 NF3DWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn72TWM2OD1yLkC1NFIyKM7:TR?= MYrTRW5ITVJ?
TE-5 M3K2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEWwOlMh|ryP NUntd3JQW0GQR1XS
DJM-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkexTWM2OD1yLkC1NVQzKM7:TR?= MmnvV2FPT0WU
NB17 NYfJUHpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEWyNFch|ryP NYXlNXd3W0GQR1XS
KARPAS-45 NIPVe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnUTWM2OD1yLkC1N|U5KM7:TR?= NG[0OZVUSU6JRWK=
TGBC1TKB MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7KXlVKSzVyPUCuNFU1ODVizszN NXTQVnN2W0GQR1XS
ML-2 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLJTWM2OD1yLkC1OFE1KM7:TR?= MV\TRW5ITVJ?
no-10 NGPDfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsTWM2OD1yLkC1OFc1KM7:TR?= NH\USGRUSU6JRWK=
CTV-1 NHTLeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\zSmlEPTB;MD6wOVUxOiEQvF2= NIPZUpVUSU6JRWK=
SJSA-1 M1nHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEW1NkDPxE1? NXu3NXFSW0GQR1XS
HC-1 NVfCeVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfKTWM2OD1yLkC1OVk4KM7:TR?= Ml\lV2FPT0WU
TE-12 NH3M[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQTWM2OD1yLkC1OlE{KM7:TR?= NWTVNZNZW0GQR1XS
KY821 NGXodWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT0Zpl4UUN3ME2wMlA2PjN{IN88US=> NFP1VVdUSU6JRWK=
TALL-1 NEPYOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEW3NFgh|ryP NX\GUJNCW0GQR1XS
DEL NX;hcFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TDc2lEPTB;MD6wOVcxQSEQvF2= MX7TRW5ITVJ?
TE-6 NH62OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fSeGlEPTB;MD6wOVczOiEQvF2= NI\vc5lUSU6JRWK=
SK-LMS-1 M{\mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm0TWM2OD1yLkC1PFA2KM7:TR?= NIHkNFlUSU6JRWK=
EW-1 NGj0[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HJfGlEPTB;MD6wOVg{PyEQvF2= MXrTRW5ITVJ?
8-MG-BA M1z2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxV|ZKSzVyPUCuNFU5PTFizszN M4OzeXNCVkeHUh?=
NALM-6 NIGwcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xre2lEPTB;MD6wOVk4OyEQvF2= M4PUdHNCVkeHUh?=
LB771-HNC MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yyS2lEPTB;MD6wOVk4QSEQvF2= MWnTRW5ITVJ?
HT-144 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXUlFOUUN3ME2wMlA3OTNizszN MkezV2FPT0WU
KM-H2 NUnMW5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwME[yNlEh|ryP MlTJV2FPT0WU
SF268 M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzsTWM2OD1yLkC2Nlg3KM7:TR?= Ml3aV2FPT0WU
RS4-11 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn24TWM2OD1yLkC2N|A1KM7:TR?= Mkn1V2FPT0WU
MHH-PREB-1 NFn0VXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwME[zNVkh|ryP MmW5V2FPT0WU
ATN-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHje4NKSzVyPUCuNFY{PDVizszN MnjlV2FPT0WU
BB30-HNC Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[yTWM2OD1yLkC2OFM3KM7:TR?= MWXTRW5ITVJ?
CPC-N NVfqSpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqwTWM2OD1yLkC2OVI1KM7:TR?= MnuzV2FPT0WU
NB1 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\XTWM2OD1yLkC2OlE{KM7:TR?= MX3TRW5ITVJ?
KS-1 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rrRmlEPTB;MD6wOlc1QCEQvF2= MnrEV2FPT0WU
RXF393 NEG4T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTNTIhKSzVyPUCuNFY4PjRizszN MkW0V2FPT0WU
IST-SL2 NXXQZotxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJSVljUUN3ME2wMlA4ODB2IN88US=> MoDzV2FPT0WU
GI-ME-N NIj4VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEeyPFYh|ryP MXnTRW5ITVJ?
VA-ES-BJ MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3izNmlEPTB;MD6wO|Q4PSEQvF2= NF\EWmpUSU6JRWK=
NCI-H1581 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELtS|ZKSzVyPUCuNFc1PzhizszN MX;TRW5ITVJ?
U-266 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXt[ohzUUN3ME2wMlA4PDl5IN88US=> NW\2U4M1W0GQR1XS
DMS-114 NXXRVXlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMEe1Nlgh|ryP NYOyfmtuW0GQR1XS
NCI-H187 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfuTWM2OD1yLkC3O|I3KM7:TR?= MXTTRW5ITVJ?
SW962 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMEe4N|kh|ryP M1fpcXNCVkeHUh?=
MONO-MAC-6 M37yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf4bWZ2UUN3ME2wMlA4QTh4IN88US=> NYf6N2hQW0GQR1XS
MOLT-16 NYPlNWdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnixTWM2OD1yLkC4NVIyKM7:TR?= NFiwZlBUSU6JRWK=
KNS-42 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH62eFJKSzVyPUCuNFgyPjFizszN MVvTRW5ITVJ?
CMK Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jLRmlEPTB;MD6wPFIzPSEQvF2= Mnf0V2FPT0WU
Ramos-2G6-4C10 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\6R5RKSzVyPUCuNFgzOjVizszN MXrTRW5ITVJ?
Daudi NYLLZok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEiyOVYh|ryP Mo\aV2FPT0WU
NCI-H510A M1[1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYeyV4pQUUN3ME2wMlA5OzN4IN88US=> NFHTVFJUSU6JRWK=
LB831-BLC NUnJZWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzMWIpYUUN3ME2wMlA5PTZzIN88US=> NXX5[2FxW0GQR1XS
HEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7OdWFKSzVyPUCuNFg3PjhizszN MmnQV2FPT0WU
LU-134-A NW\3TWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rNcmlEPTB;MD6wPFcxQCEQvF2= NWXs[YtoW0GQR1XS
NCI-H1694 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jiU2lEPTB;MD6wPFc1PCEQvF2= MXLTRW5ITVJ?
KGN Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEi3OVkh|ryP NX6zNI1mW0GQR1XS
A253 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD1yLkC4PFIzKM7:TR?= Mn;TV2FPT0WU
DG-75 M{fYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D2SGlEPTB;MD6wPFkzOiEQvF2= NFPuNnJUSU6JRWK=
MOLT-4 NIj5WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuwdpNKSzVyPUCuNFg6QDNizszN M3vyTHNCVkeHUh?=
NCI-SNU-5 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzpUGFKSzVyPUCuNFkzPThizszN MX3TRW5ITVJ?
ONS-76 NXHPZWNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTi[YtKSzVyPUCuNFkzPzZizszN M1fldHNCVkeHUh?=
NCI-H446 NFLTTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXhUHdKSzVyPUCuNFk1PjJizszN M4rXRXNCVkeHUh?=
COR-L279 NXnKNWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLzTWM2OD1yLkC5OVU3KM7:TR?= NVvGSolJW0GQR1XS
Calu-6 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjNd2lKSzVyPUCuNFk2QThizszN MYDTRW5ITVJ?
BC-3 M33PUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLiS2V2UUN3ME2wMlA6PjZ{IN88US=> NXXMTlR{W0GQR1XS
NCI-H2126 NUe5R4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:1ZmlEPTB;MD6wPVc6OSEQvF2= MVTTRW5ITVJ?
NCI-H1882 NUXWTnozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\6TWM2OD1yLkC5PFA6KM7:TR?= NGHxSpBUSU6JRWK=
BB65-RCC NGfJb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[2V4p[UUN3ME2wMlExOjl2IN88US=> NULxNYk5W0GQR1XS
DU-4475 NEPveZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHIeYFHUUN3ME2wMlExPDB5IN88US=> NW\YUI9UW0GQR1XS
NCI-H526 M2LO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37acWlEPTB;MD6xNFQ1KM7:TR?= NHe4eoxUSU6JRWK=
NEC8 M1vKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXziVnVsUUN3ME2wMlExPTJ3IN88US=> MVvTRW5ITVJ?
NCI-H1304 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHVTWM2OD1yLkGwOVk1KM7:TR?= NX;F[XdEW0GQR1XS
L-540 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUC3NFgh|ryP NUjpfpI1W0GQR1XS
NCI-SNU-16 NVW1dW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHHZ3ZGUUN3ME2wMlExPzR{IN88US=> NUTac2l7W0GQR1XS
HD-MY-Z NVTYXGhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5[mlEPTB;MD6xNFg2PiEQvF2= MX\TRW5ITVJ?
K-562 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37kXGlEPTB;MD6xNFg2QCEQvF2= NGTBcHFUSU6JRWK=
JAR NE[yZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMUC5NlUh|ryP NV3jeVZIW0GQR1XS
MZ2-MEL NHrneGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[2Z3pKSzVyPUCuNVExPSEQvF2= M3XhOXNCVkeHUh?=
L-363 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMUGwO|kh|ryP M4LtWnNCVkeHUh?=
BV-173 NInqPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu3[ohKSzVyPUCuNVEzPDNizszN M2jjV3NCVkeHUh?=
NCI-H524 NHyzOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvNRVNMUUN3ME2wMlEyOjd2IN88US=> NXP6b5JwW0GQR1XS
EoL-1-cell MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjFToJVUUN3ME2wMlEyPjd{IN88US=> MkPJV2FPT0WU
K052 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMUG3NVIh|ryP MlPTV2FPT0WU
TK10 NUPqNo44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFThVphKSzVyPUCuNVE4OjhizszN NILje3FUSU6JRWK=
KU812 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMUKwOFQh|ryP MWjTRW5ITVJ?
RPMI-8226 NITrT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrnVmpKSzVyPUCuNVIxPTJizszN M3r5NXNCVkeHUh?=
MZ7-mel MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUKyN|ch|ryP NITkNW9USU6JRWK=
SK-PN-DW MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4RXlTUUN3ME2wMlEzOjh5IN88US=> MWTTRW5ITVJ?
SR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD1yLkGyOFQyKM7:TR?= NFH5eHdUSU6JRWK=
RPMI-6666 NXrF[Yt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ufJpKSzVyPUCuNVI4PDNizszN MnvBV2FPT0WU
no-11 NVjicHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUK4Olkh|ryP NIixWmRUSU6JRWK=
EW-3 NECxbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X1VmlEPTB;MD6xNlg6OyEQvF2= NXLUbGVZW0GQR1XS
LAMA-84 NUDzd4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Le|dKSzVyPUCuNVMyQDdizszN NGn1VYJUSU6JRWK=
HT M{Oxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1yLkGzOVc1KM7:TR?= MoTZV2FPT0WU
KP-N-RT-BM-1 Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W1O2lEPTB;MD6xN|YyOiEQvF2= NFfhU3hUSU6JRWK=
NCI-H747 NUnNfGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XkOmlEPTB;MD6xN|ch|ryP MmSyV2FPT0WU
NCCIT MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH0WIVQUUN3ME2wMlE{QTN7IN88US=> NUnrUGpjW0GQR1XS
MLMA MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLodolXUUN3ME2wMlE1OTZ5IN88US=> M3XsenNCVkeHUh?=
LP-1 NIrxSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjSbFJKSzVyPUCuNVQzPCEQvF2= M4nSVXNCVkeHUh?=
CAL-148 NHfteINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMUS0PFMh|ryP MljuV2FPT0WU
GB-1 NUDYNm5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET3bI1KSzVyPUCuNVQ2OjZizszN NEnYcIVUSU6JRWK=
COR-L88 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMUS4NFIh|ryP NIHjOo1USU6JRWK=
NKM-1 NUXHXmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nUOGlEPTB;MD6xOFkxPiEQvF2= MUTTRW5ITVJ?
NB5 M4C1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUW0OlIh|ryP NVnufZk2W0GQR1XS
SH-4 NX7TToRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjiTIlKSzVyPUCuNVU1PjZizszN NFr5epBUSU6JRWK=
EM-2 NILjeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUW0Olch|ryP NYPlfZVsW0GQR1XS
TGBC24TKB NV;vbFJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMUW2OVkh|ryP NILUO45USU6JRWK=
SCLC-21H M1H2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXNW2JKSzVyPUCuNVU4ODJizszN MY\TRW5ITVJ?
COLO-684 NIr2[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMUW3NlEh|ryP MlvWV2FPT0WU
KINGS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMUW5NUDPxE1? M1nNdnNCVkeHUh?=
LS-123 NY\UNo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG2XXVKSzVyPUCuNVU6OTdizszN MV;TRW5ITVJ?
MC116 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMU[xOVgh|ryP NILkdpRUSU6JRWK=
SU-DHL-1 M2O5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\NS4xXUUN3ME2wMlE3OjB4IN88US=> NX\4S3JuW0GQR1XS
NCI-H64 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqzVpJKSzVyPUCuNVY{PDdizszN NV:yWmp3W0GQR1XS
HCE-T NXXhUppDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TQXmlEPTB;MD6xOlUxPCEQvF2= M1mzcnNCVkeHUh?=
LOXIMVI M321TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e3cmlEPTB;MD6xOlk1QSEQvF2= NYO3Xo82W0GQR1XS
ARH-77 NGrVPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHmNGJJUUN3ME2wMlE4Ozd7IN88US=> M17Zd3NCVkeHUh?=
DOHH-2 NGTvUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMUe2O|Ih|ryP M4jWTXNCVkeHUh?=
COLO-320-HSR NGrSXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzXS3RTUUN3ME2wMlE5OTV2IN88US=> MWTTRW5ITVJ?
NB6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LzSGlEPTB;MD6xPFU3PiEQvF2= NEDhcmhUSU6JRWK=
L-428 M3XLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfMTWM2OD1yLkG4PFE{KM7:TR?= MUfTRW5ITVJ?
SNB75 M4Ps[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfqTWM2OD1yLkG4PFI1KM7:TR?= MX;TRW5ITVJ?
NCI-H2141 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUmwNVEh|ryP Moq0V2FPT0WU
KARPAS-299 NH7JNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXWXHZKSzVyPUCuNVkzPDFizszN MkXLV2FPT0WU
LC4-1 NXvHNHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\VZWlKSzVyPUCuNVk2ODJizszN M{TST3NCVkeHUh?=
UACC-257 M1\0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMUm5OFch|ryP M2npSHNCVkeHUh?=
EVSA-T Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvQeIVTUUN3ME2wMlIxOzF{IN88US=> NGLJW2FUSU6JRWK=
JiyoyeP-2003 M375OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL1TWM2OD1yLkKwOFc4KM7:TR?= Mk\DV2FPT0WU
NCI-H720 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PqZ2lEPTB;MD6yNFUzPSEQvF2= NGfw[5VUSU6JRWK=
GAK NWCzcGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqwTWM2OD1yLkKxNVg6KM7:TR?= NHrtdnhUSU6JRWK=
HH NVq1SGJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ESWlEPTB;MD6yNVQxPSEQvF2= MX\TRW5ITVJ?
NCI-H1436 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMkG0OlQh|ryP NHLubWpUSU6JRWK=
GR-ST M3nYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXucI06UUN3ME2wMlIyPDh6IN88US=> MYXTRW5ITVJ?
BC-1 M3S1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMkK2NVYh|ryP MXjTRW5ITVJ?
SIG-M5 NXHYTZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK5N2JFUUN3ME2wMlIzPzJ5IN88US=> MnPyV2FPT0WU
NCI-H345 NX60bXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDoblBKSzVyPUCuNlM5ODVizszN MmHTV2FPT0WU
OPM-2 NIrwN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIewU21KSzVyPUCuNlM5QDJizszN NV3NbIZlW0GQR1XS
LB1047-RCC NGq4NmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMkS0NUDPxE1? M2fVTXNCVkeHUh?=
CTB-1 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMkS0PVMh|ryP Mn7tV2FPT0WU
A3-KAW NYi1SlZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7iTWM2OD1yLkK1N|QyKM7:TR?= NVG2[41wW0GQR1XS
SF126 NGDwc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFWYxKSzVyPUCuNlU{QDNizszN M{HVUnNCVkeHUh?=
KARPAS-422 NX;hTo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HaZWlEPTB;MD6yOVQ{PSEQvF2= MmHKV2FPT0WU
MEG-01 NUj5cVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMkW2O|Mh|ryP MVzTRW5ITVJ?
NCI-H209 NF3IS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn22TWM2OD1yLkK2N|c1KM7:TR?= MliwV2FPT0WU
SBC-1 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrQO4VyUUN3ME2wMlI3PSEQvF2= MlKyV2FPT0WU
K5 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMk[5PFQh|ryP M1HVW3NCVkeHUh?=
QIMR-WIL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjzXnpjUUN3ME2wMlI4OTV3IN88US=> NF[xSWxUSU6JRWK=
NMC-G1 NVvkVHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M360NGlEPTB;MD6yPFIyPyEQvF2= Ml;ZV2FPT0WU
IST-MES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37YS2lEPTB;MD6yPVI{QCEQvF2= M3S1NHNCVkeHUh?=
SW684 NW\E[4xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;aWlNKSzVyPUCuN|AxPDdizszN M4TWbXNCVkeHUh?=
MV-4-11 NX;wO|BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n5OGlEPTB;MD6zNFc5QCEQvF2= MUHTRW5ITVJ?
LAN-6 M{\zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjZTWM2OD1yLkOxOVczKM7:TR?= NX;XbXhYW0GQR1XS
RH-1 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:4RW1mUUN3ME2wMlMyQDdzIN88US=> M4HxcHNCVkeHUh?=
CP66-MEL NYm2eIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwM{G4O|gh|ryP M3LQfXNCVkeHUh?=
EC-GI-10 NGroWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[wZnRKSzVyPUCuN|I6QDdizszN NXnnfGd5W0GQR1XS
GDM-1 M1X6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLrZYhWUUN3ME2wMlM{ODV7IN88US=> M4fLR3NCVkeHUh?=
IST-SL1 NW\3XmVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HRc2lEPTB;MD6zOFkyPCEQvF2= M4jlVHNCVkeHUh?=
KMOE-2 NHPvVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLETWM2OD1yLkO1NVc2KM7:TR?= MY\TRW5ITVJ?
OS-RC-2 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPkTWM2OD1yLkO1OVQ1KM7:TR?= NG\PRXNUSU6JRWK=
HDLM-2 M4HB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfOeGFKSzVyPUCuN|c5OTRizszN M4XwVnNCVkeHUh?=
DSH1 NIO3fXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPxTWM2OD1yLkO4OlMyKM7:TR?= M{iyV3NCVkeHUh?=
LS-1034 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX74U3d3UUN3ME2wMlM5QTV2IN88US=> Mn3DV2FPT0WU
LB373-MEL-D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CySmlEPTB;MD6zPVE6PyEQvF2= M2HleHNCVkeHUh?=
GOTO M4rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXZNnNKSzVyPUCuOFIyOThizszN MYPTRW5ITVJ?
MRK-nu-1 NF:zSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\iWIR1UUN3ME2wMlQzOjB3IN88US=> M{nLZ3NCVkeHUh?=
SK-MM-2 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\KTWM2OD1yLkSzOFQzKM7:TR?= MkD0V2FPT0WU
BOKU M1z1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPVbXZKSzVyPUCuOFM4QTJizszN M1rwbHNCVkeHUh?=
NOMO-1 M36yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljqTWM2OD1yLkSzPFYh|ryP NGDhPG5USU6JRWK=
J-RT3-T3-5 NIiw[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4NXVUUUN3ME2wMlQ1QDd6IN88US=> NGfaRlZUSU6JRWK=
COLO-668 NELWTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljsTWM2OD1yLkS1OlY5KM7:TR?= MVTTRW5ITVJ?
SF539 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG0TWM2OD1yLkS4Olg1KM7:TR?= MlXhV2FPT0WU
LB2518-MEL M1jjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;hdlhWUUN3ME2wMlQ6PzB|IN88US=> MUHTRW5ITVJ?
TE-441-T NILTNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXjTWM2OD1yLkWwNVIh|ryP NGnJ[ZNUSU6JRWK=
MDA-MB-134-VI NHe5bJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNUC5NlEh|ryP MkXoV2FPT0WU
SCC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLhNIxKSzVyPUCuOVE5PzNizszN MVHTRW5ITVJ?
KLE MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNUKxO|Eh|ryP MXPTRW5ITVJ?
LB2241-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNUK1NlUh|ryP NIrU[GRUSU6JRWK=
NCI-H1417 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzrTWM2OD1yLkWzOFM2KM7:TR?= M2fNSHNCVkeHUh?=
NCI-H2081 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNUi2NVEh|ryP MW\TRW5ITVJ?
NCI-H1522 NVzudpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3iTWM2OD1yLkW5N|g{KM7:TR?= NXf6S2dIW0GQR1XS
NCI-H889 M2rzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0emlEPTB;MD61PVg1PCEQvF2= MVLTRW5ITVJ?
CGTH-W-1 M1foPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNkC3OVUh|ryP M3K1ZXNCVkeHUh?=
EB-3 NIrO[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq1[FZKSzVyPUCuOlEyPTNizszN MYPTRW5ITVJ?
D-336MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnKTWM2OD1yLk[xO|kyKM7:TR?= NWf3[3dCW0GQR1XS
LC-1F MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNkK1PVIh|ryP NV\Cbmh3W0GQR1XS
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD1yLk[zPFAyKM7:TR?= M4XLXHNCVkeHUh?=
SK-N-FI NF3WWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[5TWM2OD1yLk[zPVEh|ryP NEPHRo5USU6JRWK=
NCI-H69 M4XOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\reG8yUUN3ME2wMlY1QDd7IN88US=> NWW5TXR5W0GQR1XS
SCH NUPuXmN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv3Z|dKSzVyPUCuOlYxOjNizszN NUe4O2FRW0GQR1XS
LS-513 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1TJFKSzVyPUCuOlczPTlizszN MofIV2FPT0WU
CP67-MEL NF\lOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDLTWM2OD1yLk[3OVk3KM7:TR?= MoOyV2FPT0WU
GCIY NFz5UXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XCXWlEPTB;MD63NFM3OyEQvF2= NWXWTG9DW0GQR1XS
SHP-77 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICz[ZVKSzVyPUCuO|A4OzRizszN M2XTRXNCVkeHUh?=
EHEB NV7LR3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PXOmlEPTB;MD63NVg2PCEQvF2= MoS2V2FPT0WU
D-247MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;zd2hOUUN3ME2wMlc{OjN{IN88US=> NIC4eHdUSU6JRWK=
Raji M1nSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKxc|E1UUN3ME2wMlc1QTh7IN88US=> NXjOO|BZW0GQR1XS
MPP-89 NIiyO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXZTWM2OD1yLke1PVc5KM7:TR?= MWLTRW5ITVJ?
EKVX MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HXOGlEPTB;MD63PVA4OyEQvF2= NUn1RYt1W0GQR1XS
HCC2218 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfuUlRwUUN3ME2wMlc6OTNzIN88US=> MXzTRW5ITVJ?
KNS-81-FD MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL3Wo1KSzVyPUCuPFExOTFizszN NW\3[GJ[W0GQR1XS
HCC2157 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Do[2lEPTB;MD64OFk2OSEQvF2= NWrxZnVrW0GQR1XS
BT-474 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX0XIVKSzVyPUCuPFg5PTRizszN NFPJeGFUSU6JRWK=
NCI-H748 NF[2RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32xO2lEPTB;MD65NVIh|ryP MWDTRW5ITVJ?
EW-24 NWLZ[FlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwOUKwNFIh|ryP Mlj2V2FPT0WU
D-263MG Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f6b2lEPTB;MD65OFUyOiEQvF2= NUThPGFVW0GQR1XS
OMC-1 NG\TeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfNU3VKSzVyPUCuPVY{PzNizszN MXjTRW5ITVJ?
NCI-H2196 NIftUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPoTWM2OD1yLkm3O|c4KM7:TR?= M3TTNHNCVkeHUh?=
HAL-01 NE\jT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fHcWlEPTB;MD65PVg4OiEQvF2= MVfTRW5ITVJ?
NCI-H2107 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwMEG4OVQh|ryP MX3TRW5ITVJ?
LB996-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkbWlEPTB;MT6wPFA2OSEQvF2= MnTCV2FPT0WU
NCI-H1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUC2O{DPxE1? M2LQcnNCVkeHUh?=
CHP-126 NIjq[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LqVWlEPTB;MT6xOlE6QSEQvF2= NYX6fnNrW0GQR1XS
NB69 NV3wZWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMk[xOFgh|ryP MkjpV2FPT0WU
CAS-1 M3m3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLSTZhKSzVyPUGuN|QzOzFizszN M1HFbHNCVkeHUh?=
JVM-3 NGfoem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwNEe4OVUh|ryP NFjnWmpUSU6JRWK=
DMS-153 MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHqzWFlKSzVyPUGuOVc3PzRizszN NGXmeGFUSU6JRWK=
SK-MEL-2 NWrUUGplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jQd2lEPTB;MT63NVc5QSEQvF2= MU\TRW5ITVJ?
NCI-H1155 NVTvZ4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoniTWM2OD1zLkezOlc3KM7:TR?= NFK5cYZUSU6JRWK=
NCI-H1092 M2nOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlUGlEPTB;MT63OlE5OiEQvF2= M{C2XnNCVkeHUh?=
LU-165 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGzTWM2OD1zLki2OFc3KM7:TR?= NWnKS3A3W0GQR1XS
HL-60 M4ni[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDwTWM2OD1zLkm5PVA5KM7:TR?= M4rCc3NCVkeHUh?=
REH M33o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PyTGlEPTB;Mj6wNFU5OiEQvF2= NUj5WGRzW0GQR1XS
JVM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3npNWlEPTB;Mj6wOlE{PSEQvF2= MUnTRW5ITVJ?
MN-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;zTWM2OD1{LkG3N|A5KM7:TR?= M3v5OHNCVkeHUh?=
SCC-15 M1GxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO1TWM2OD1{LkKwNlch|ryP NXLzd5ppW0GQR1XS
SNU-C1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwMkGzOFMh|ryP NIe1U5ZUSU6JRWK=
SK-MEL-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnXdZRKSzVyPUKuN|IxPDdizszN M2TwNXNCVkeHUh?=
TGW MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTRV|hDUUN3ME2yMlM2ODJ5IN88US=> MX;TRW5ITVJ?
CA46 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwN{W5Olch|ryP Ml:wV2FPT0WU
NCI-H23 M1KwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnTU4lPUUN3ME2yMlgxPzlzIN88US=> MlvDV2FPT0WU
MMAC-SF NW\2fYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fXUGlEPTB;Mj64OlYzQCEQvF2= MYjTRW5ITVJ?
NCI-H2171 NILyTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPiVpZKSzVyPUOuNFM1PDhizszN NVO4enE6W0GQR1XS
A704 M1Hm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwMUSxPVQh|ryP NVPIO2xzW0GQR1XS
DB NHLUOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPzWWpKSzVyPUOuNlU2PzZizszN NHzR[3RUSU6JRWK=
NCI-H719 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHWOVhHUUN3ME2zMlMxOzh2IN88US=> M1jIW3NCVkeHUh?=
MC-CAR NVXOTJF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2yUGxKSzVyPUOuOVQ5OTdizszN NH\5endUSU6JRWK=
SIMA NXLjTnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwNUi0NVYh|ryP MVvTRW5ITVJ?
SW872 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwN{ixNFEh|ryP MVvTRW5ITVJ?
HCC1187 NW\0SFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwN{izNVUh|ryP MWPTRW5ITVJ?
EW-13 M4[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\qWXBuUUN3ME2zMlg{PDF5IN88US=> M4Do[XNCVkeHUh?=
NCI-SNU-1 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPUfoJKSzVyPUSuNlE6QTlizszN MlvHV2FPT0WU
NCI-H226 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PRO2lEPTB;ND6zN|YxPiEQvF2= Mn7IV2FPT0WU
RPMI-8866 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fVXWlEPTB;ND6zOlAzQSEQvF2= M4m3eHNCVkeHUh?=
OCI-AML2 NWfnTYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwNUWyN{DPxE1? NF[5XnJUSU6JRWK=
LU-65 NUPM[lQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fxd2lEPTB;ND65N|A{OyEQvF2= M{\XPHNCVkeHUh?=
SK-N-DZ NFz4UJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[0[HM5UUN3ME21MlY{PDZ3IN88US=> MX7TRW5ITVJ?
NB14 M1vzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1RXFKSzVyPUWuPVcyOzVizszN MV7TRW5ITVJ?
COLO-829 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwM{OzOVkh|ryP MWrTRW5ITVJ?
MHH-CALL-2 NV3x[3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:1TWM2OD14LkWxOVA5KM7:TR?= MXHTRW5ITVJ?
NCI-H1770 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTZwNk[5NFQh|ryP M2\Te3NCVkeHUh?=
ECC4 NFryVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZwOEKxO|kh|ryP MYXTRW5ITVJ?
A498 M{\uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XEcmlEPTB;Nj64O|E6OiEQvF2= MlS1V2FPT0WU
DMS-79 M4TlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJV4FKSzVyPUeuNFQ2OTJizszN NYrLVGtsW0GQR1XS
P30-OHK NUOzdIlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaTWM2OD15LkKxPVA3KM7:TR?= MX3TRW5ITVJ?
D-502MG NYn0OmZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG4TWM2OD15Lkm4N|Yh|ryP MonOV2FPT0WU
RCC10RGB NX3OcpEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3pWYtKSzVyPUiuNFYzQCEQvF2= MX\TRW5ITVJ?
U-698-M M1LDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRThwMkmyNlYh|ryP Mm\FV2FPT0WU
BB49-HNC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX4fXpSUUN3ME25MlQzOjZ3IN88US=> M1vOXXNCVkeHUh?=
ES1 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;zU5hLUUN3ME25MlY5QTV4IN88US=> NIfuSZJUSU6JRWK=
MFM-223 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjXTFd4UUN3ME2xNE46QTJ5IN88US=> MmTRV2FPT0WU
C2BBe1 NIK0cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT3fZNKSzVyPUGxMlM2OjNizszN MXHTRW5ITVJ?
EB2 NF6zSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n3[WlEPTB;MUKuOlg5OSEQvF2= M4T3VHNCVkeHUh?=
C8166 NW\pNZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HYWGlEPTB;MUOuPFMxOyEQvF2= Mlm0V2FPT0WU
ES3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlqyTWM2OD1zMz65PVc4KM7:TR?= MmjSV2FPT0WU
NCI-H1650 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjl[mRDUUN3ME2xOk4{PzZ3IN88US=> M3ntVXNCVkeHUh?=
Mo-T NGHETIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2xTWM2OD1zNz60NFI6KM7:TR?= NGDIZYpUSU6JRWK=
NB7 NFPZNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjTR29KSzVyPUG3Mlc1PjdizszN M2TBbHNCVkeHUh?=
ES7 NXXqeWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF7LkW1NFch|ryP NV7wfnM6W0GQR1XS
ES5 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f6d2lEPTB;MkGuO|Y4OSEQvF2= MUDTRW5ITVJ?
MSTO-211H M333bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHxTWpKSzVyPUKxMlg5PThizszN NW\Zc|ZjW0GQR1XS
U-87-MG NF;MUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\1TWM2OD1{NT6xPVY3KM7:TR?= MWXTRW5ITVJ?
THP-1 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ7LkeyNFEh|ryP M{exOXNCVkeHUh?=
NB10 M3jEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrzSmhKSzVyPUOwMlI3QTRizszN MYXTRW5ITVJ?
NH-12 NUXUW|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3XU2NJUUN3ME2zN{4zODF5IN88US=> NWDWdIpvW0GQR1XS
COLO-824 M4jHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS3TWM2OD1|ND6xNFA3KM7:TR?= MWPTRW5ITVJ?
SKM-1 NVWyb3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN5Lki0NlIh|ryP NYiyR3JXW0GQR1XS
NCI-H1838 NWG3d2E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fDdmlEPTB;M{iuN|c6PyEQvF2= NXT5d2Y{W0GQR1XS
RL Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHOb5lKSzVyPUO5MlI1PzdizszN MXTTRW5ITVJ?
COLO-800 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYfYpKSzVyPUSwMlA4PzNizszN NXnuOIlJW0GQR1XS
KG-1 NHXtNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvpTWM2OD12MD64PVU2KM7:TR?= MUTTRW5ITVJ?
TUR MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DVXWlEPTB;NEGuOlM6QSEQvF2= NFrUVXBUSU6JRWK=
LNCaP-Clone-FGC NYnQWZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLzTWM2OD12MT65NFE4KM7:TR?= MX\TRW5ITVJ?
NCI-H322M M{PNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULQcWxCUUN3ME20Nk42QTh2IN88US=> NYfzdXY4W0GQR1XS
LNCaP  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHaNW1KSzVyPUmxMlMhdk1? NVTQfXFIOjV3MEWxO|Q>
C4-2 M2Xjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLZWFhFUUN3ME24JI5O M1u3R|I2PTB3MUe0
JURKAT Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTBT4EzPCCq MoPWTWM2OD12MU[uOlYhdk1? MYqyOFUyQTl7NR?=
MOLT-4 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS3c|QzPCCq NWWzcWZNUUN3ME2yPFU{NjVibl2= NFzIV4szPDVzOUm5OS=>
REH M3e0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTJNlQhcA>? M3y1U2lEPTB;Mki3MlY5KG6P MmDHNlQ2OTl7OUW=
NALM-6 NFfIVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfTNlQhcA>? M{PuVmlEPTB;M{SzN|Ahdk1? MnGwNlQ2OTl7OUW=
RS 4;11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTtbIwzPCCq NVrPdVhsUUN3ME21NVkvODVibl2= NX3hcVMyOjR3MUm5PVU>
697 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW2NlQhcA>? M1LmcGlEPTB;MkGwO{4yKG6P MoHVNlQ2OTl7OUW=
SIL-ALL MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyOEBp NXPGb4Y2UUN3ME2xPVkvPzdibl2= MV2yOFUyQTl7NR?=
CEM MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHYfHAzPCCq Mle4TWM2OD13Mj6xPEBvVQ>? Mn\iNlQ2OTl7OUW=
P12 M3HT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f3NlI1KGh? NU[0NJJQUUN3ME2zPU4zPyCwTR?= NFS1c3kzPDVzOUm5OS=>
NALM-16 MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LVVVI1KGh? MoPCTWM2OD17Nj6yPEBvVQ>? M2jveVI1PTF7OUm1
JURKAT MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC0PEBp NV24[WU6UUN3ME2xOE45PCCwTR?= Mm\ONlQ2OTl7OUW=
MOLT-4 NXPnOVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjldlA1QCCq NWSxcY9VUUN3ME2yOk43KG6P MU[yOFUyQTl7NR?=
REH NU\zcGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL4R5o1PDhiaB?= NE[0WIxKSzVyPUS0MlcyKG6P M2nQRlI1PTF7OUm1
NALM-6 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVG0PEBp NVvnNZE6UUN3ME2yN{4zPiCwTR?= NVXqSWdFOjR3MUm5PVU>
RS 4;11 M3K0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTJXog1QCCq NHvFWmtKSzVyPUG2OE4zQCCwTR?= MUeyOFUyQTl7NR?=
697 NWrVSpRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOxOFghcA>? M1nSSmlEPTB;M{C1MlMhdk1? MUGyOFUyQTl7NR?=
SIL-ALL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK0PEBp Mk\iTWM2OD15ND62NkBvVQ>? MVyyOFUyQTl7NR?=
CEM M4\5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjpOFghcA>? MVXJR|UxRTJ2LkW1JI5O NXHpd4VqOjR3MUm5PVU>
P12 NYfNOo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3foT|Q5KGh? NXrUdYVUUUN3ME2xPE41PiCwTR?= Ml;BNlQ2OTl7OUW=
NALM-16 NF3v[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\EWlQ5KGh? M2XiWGlEPTB;NkOuNlQhdk1? NF7HbXEzPDVzOUm5OS=>
JURKAT M1;HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp M3rQU2lEPTB;Mz62OUBvVQ>? NI\T[HUzPDVzOUm5OS=>
MOLT-4 NULpUIl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH0V25lPzJiaB?= NX\mTFJ{UUN3ME23MlM6KG6P NHX0NGMzPDVzOUm5OS=>
REH M2izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vkRVczKGh? Mk\TTWM2OD1zNj6wNUBvVQ>? NYDPWm5kOjR3MUm5PVU>
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLOlczKGh? MoPLTWM2OD1zLke4JI5O NX;kOWNHOjR3MUm5PVU>
RS 4;11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NkBp NHrS[IJKSzVyPUSuN|ghdk1? M1vVbVI1PTF7OUm1
697 M{LUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi3NkBp M2HMc2lEPTB;N{SuNlghdk1? MmDpNlQ2OTl7OUW=
SIL-ALL M2\kbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TKdFczKGh? NEPKXlhKSzVyPUeuNkBvVQ>? M{TmTVI1PTF7OUm1
CEM NHHBOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrUO|IhcA>? NVTYUGlwUUN3ME21MlQzKG6P NX3FdJJNOjR3MUm5PVU>
P12 NH[xbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHWcms4PzJiaB?= MXfJR|UxRTZwM{egcm0> M3rYN|I1PTF7OUm1
NALM-16 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TUTFczKGh? MUXJR|UxRTd5LkezJI5O NWDHRmZ6OjR3MUm5PVU>
Y79 Mn\NRZBweHSxc3nzJGF{e2G7 NVztZlNOOS13MDDuUS=> MlzYNVIwOjRiaB?= NVvQT|doTE2VTx?= M{XrVIlv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=> M1nOO|I1OzZ4Nk[1
WER-Rb-1 NEjoTXFCeG:ydH;zbZMhSXO|YYm= M4TsWFEuPTBibl2= M4Ho[|EzNzJ2IHi= Mnf2SG1UVw>? Mme3bY5lfWOnZDDhdI9xfG:|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU MXuyOFM3PjZ4NR?=
G7 NX3TdHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD1|LkOgcm0> MXGyOFIxPDd|Mx?=
G166 M4jVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPvTWM2OD15LkCgcm0> NYHMU5NGOjR{MES3N|M>
CB660 M{TMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtemlKSzVyPU[uOEBvVQ>? MXeyOFIxPDd|Mx?=
CB1117 NELnO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j6[mlEPTB;MUWuOkBvVQ>? NVfMUHhCOjR{MES3N|M>
KB-3-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P4OWlEPTB;MT60PEDDuSByLkWzJI5O NHmzboMzOzl4MkS0OS=>
KB-8-5-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LnbWlEPTB;NT6wNUDDuSB{LkCxJI5O MVqyN|k3OjR2NR?=
KB-C-1 NUHMTGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPWTWM2OD1zNj63OkDDuSB2LkWxJI5O M4XzbFI{QTZ{NES1
KB-V-1 M{fmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHVSZlKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?= MmrrNlM6PjJ2NEW=
OVCAR-8 NGfaeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzhTWM2OD15LkG5JOKyKDNwNkCgcm0> MmXMNlM6PjJ2NEW=
NCI-ADR-RES NHuzWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfRenNkUUN3ME2xNlc{NjNyINMxJFE6OS5{MDDuUS=> Mkj2NlM6PjJ2NEW=
MCF7 NX3OT3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHVc|AzUUN3ME21MlEyKMLzIEGuOFchdk1? NWnGdGpMOjN7NkK0OFU>
MCF7-FLV1000 NF7vVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>? NF7kdW4zOzl4MkS0OS=>
S1 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2LkOwJOKyKDRwN{Wgcm0> NHr3OFYzOzl4MkS0OS=>
S1-M1-80 NYTn[nJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\tdGlEPTB;Mk[xMlA3KMLzIES4MlI2KG6P M2jJRlI{QTZ{NES1
CORL-23/P NUjkeGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwM{igxtEhOS5{NTDuUS=> MYmyN|k3OjR2NR?=
CORL-23/R M3zjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPEOZN[UUN3ME21MlE3KMLzIEGuPFMhdk1? M3;lblI{QTZ{NES1
NIH3T3 M2\wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWxc5F7UUN3ME20NE43OCEEsTC0Mlk4KG6P NFz0OFEzOzl4MkS0OS=>
NIH3T3-G185 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHlTWM2OD1{NEGzMlQxKMLzIESyN{43PiCwTR?= NX7rXnhwOjN7NkK0OFU>
pcDNA-HEK293 NITkVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iTWM2OD1{Lke1JOKyKDBwNkegcm0> MlPINlM6PjJ2NEW=
MDR19-HEK293 NVrMNnZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\2OIZtUUN3ME24OU42OCEEsTCxN{43PyCwTR?= NFezZpQzOzl4MkS0OS=>
R482-HEK293 NVTxeJZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ3Lkm3JOKyKDRwOUWgcm0> NUDuNGdnOjN7NkK0OFU>
MRP1-HEK293 NYr5fIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGbmlEPTB;Mj65PUDDuSBzLkS5JI5O MVmyN|k3OjR2NR?=
SF188 NYSzeGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G4fVExNTFyMDDuUS=> MWWyOE06PiCq NYXye|lHTE2VTx?= NXv5cIxVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck0h\GWyZXTlcpQhdWGwbnXy MVyyN|g5PzZ2NR?=
T98G Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PzOVExNTFyMDDuUS=> MVyyOE06PiCq NGGxN49FVVOR NVPZRodKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdi1iZHXw[YRmdnRibXHucoVz NV:zOI9lOjN6OEe2OFU>
DU145 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL3SG1UVw>? Mni3TWM2OOLKvE[wJI5O NVr5cIg5OjN6OES0Nlg>
LNCaP  NX7OWVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn65SG1UVw>? MUfJR|Ux6oj:N{Wgcm0> NFTnOYUzOzh6NESyPC=>
PC3 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITsPVhFVVOR M3HKeWlEPTEkiMyxO|Uhdk1? NUfMZY5OOjN6OES0Nlg>
RT4 M3rKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5VWliUUN3ME2yO{4zOSCwTR?= NYnLbI1TOjN5OUK2N|k>
5637 NWXSdHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBeWpKSzVyPUS1MlQ4KG6P NEfRWYMzOzd7Mk[zPS=>
T24 M1Hkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P6b2lEPTB;N{muNVIhdk1? M2HFOlI{Pzl{NkO5
MCF7  M1rsUGZ2dmO2aX;uJGF{e2G7 M3rTclExOCCwTR?= NWTOW5VEOSCq MmjNSG1UVw>? NW\abm1UemWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT|CpHNoczFuwrDQd|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?= MVeyN|c4ODJ2NB?=
KB-V1  M{LaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW2TWM2OD1|LkmyJO69VQ>? NYHVS3U1OjN3OUOxPVY>
Hec50co MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVibl2= M4HvXVI{OTR4Nki3
MDA-MB-468 MUPBdI9xfG:|aYOgRZN{[Xl? M3nQPVEwPS9zMDDuUS=> NH[0fYQzPC92OD:3NkBp M4XYbWROW09? MXvpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{TVOlI{OTR2Mkm0
MCF10A MVTBdI9xfG:|aYOgRZN{[Xl? MXuxM|UwOTBibl2= MlnyNlQwPDhxN{KgbC=> M3v3[2ROW09? MnnIbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{KxcVI{OTR2Mkm0
Huh-7 NVrLTJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjONU8yOC9zMECvNVAxOCCwTR?= MnO4OFghcA>? MXHk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm= NIHieXkzOjd2NUW4Oy=>
Daoy  M2T6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexMlg4PS1{NECgcm0> MUW3NkBp M{m5bmROW09? NFTwU4lKSzVyPUWgcm0> NX7OeIFQOjJ|OUCyO|k>
ONS-76 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYNU45PzVvMkSwJI5O MWK3NkBp MoPkSG1UVw>? NGDF[2ZKSzVyPUeuOUBvVQ>? MVeyNlM6ODJ5OR?=
SUM 149 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrNNE0yODBibl2= NVS1V2tkPzJiaB?= NGXm[4xqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> NXnzb|hSOjJ|MEm5N|k>
MDA-MB-231 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfqbY4xNTFyMDDuUS=> NWLyWG5mPzJiaB?= NGHsRpVqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> M2rNUlIzOzB7OUO5
HR5 NXrlWm82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf4OlQxNTFyMDDuUS=> MkDnO|IhcA>? NGm4[4JqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> NH;iOXgzOjNyOUmzPS=>
BT-474-M1 NGf1e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e3WFAuOTByIH7N NXPJOXBZPzJiaB?= NYG2O3NncW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz NX\3RmQ2OjJ|MEm5N|k>
AU565 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqyXWVtOC1zMECgcm0> M1TsTVczKGh? MUjpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= MX6yNlMxQTl|OR?=
T47D MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCNE0yODBibl2= MV23NkBp M{nibIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> MYWyNlMxQTl|OR?=
MCF7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNNE0yODBibl2= MXy3NkBp NHTnVVJqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> M3qyVVIzOzB7OUO5
HCT116p53(+/+) MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xNE0yODByIH7N MoDuNlQwPDhiaB?= NXfiPI1DcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1? Ml7vNlIzPjJzN{G=
HCT116p53(-/-) MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonZNVAuOTByMDDuUS=> MoTvNlQwPDhiaB?= NG[yfYFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>? M3fNe|IzOjZ{MUex
HeLa  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNE0yODBibl2= M3nYSFQ5KGh? M1XXfmROW09? NXT5S|NWUUN3ME21Nk46KG6P MkSzNlIxQDB{M{W=
HeLa  MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S3O|ExNTFyMDDuUS=> MV:3NkBp NVy2e4dOTE2VTx?= NYLEfoFnUUN3ME21NE42KG6P M{ixW|IzODhyMkO1
GBC MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ldZpLPzJiaB?= NFOw[VJKSzVyPUG0Mlc5KG6P M{jpfVIyQTZ3N{O5
GB-CL-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rFRVczKGh? NEn1T5lKSzVyPUWuNlIhdk1? M1fYU|IyQTZ3N{O5
Mz-ChA-2 M4PIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP2O|IhcA>? NYK5SIZYUUN3ME2zMlMyKG6P MWWyNVk3PTd|OR?=
TGBC1-TKB NIDwNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXIcmRpOTR2IHi= MoDTTWM2OD14LkeyJI5O NHjmOGczOTl4NUezPS=>
Wittier MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO3NkBp NWjuUG9tUUN3ME2zMlI3KG6P NHvRcGYzOTl4NUezPS=>
H-1 NWrI[YJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp MVXJR|UxRTlwNUSgcm0> MoX4NlE6PjV5M{m=
HuH-28 NUD2W2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH0O|IhcA>? NEjQTpNKSzVyPUGxMlE6KG6P NEnoVIkzOTl4NUezPS=>
NEC NXPrRY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5O|IhcA>? MXTJR|UxRTlwOUigcm0> NF\zXG8zOTl4NUezPS=>
REB M{Lx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC3NkBp Ml7QTWM2OD1zMz61NUBvVQ>? MknJNlE6PjV5M{m=
CC-LP-1 NHrCbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vlSFczKGh? MmG0TWM2OD13Lki0JI5O NWHUW2tCOjF7NkW3N|k>
CC-SW-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrQO|IhcA>? Mlr6TWM2OD17LkW1JI5O M{fVTFIyQTZ3N{O5
EGI-1 NEm5eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu3NkBp NVT6OZk6UUN3ME2xNE44OiCwTR?= M3\6VFIyQTZ3N{O5
Sk-ChA-1 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHaO|IhcA>? NHTESI1KSzVyPUG3MlIhdk1? MVyyNVk3PTd|OR?=
TFK-1 NV:wNnJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\TU|czKGh? M{XLcmlEPTB;MUOuOFUhdk1? MWWyNVk3PTd|OR?=
786-O MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLEOU05OCCwTR?= NX[1e3d4QTZiaB?= NIfXd5pJS2x? MlHGd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P NH7udlQzOTZ2MkO3OC=>
A498 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtOU05OCCwTR?= NXjte2JzQTZiaB?= NHm5fGlJS2x? M1LaWZN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?= MUmyNVY1OjN5NB?=
ACHN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzSVQ2NThyIH7N MYG5OkBp NUfUT2hSUEOu NF3xeVh{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= MoPzNlE3PDJ|N{S=
Caki-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DWfVUuQDBibl2= NFXBXW06PiCq NEXKd5FJS2x? NY\NPGJVe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N NV3jOmI3OjF4NEKzO|Q>
SN12C NFPQdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DKflUuQDBibl2= NYXn[3c4QTZiaB?= M1v2fGhEdA>? MnW2d5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P NUHJeXZtOjF4NEKzO|Q>
HMC-1.1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxMVExODBibl2= M2r5OlczKGh? NX;XcYVScW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n MmjDNlEzPDJzOEm=
HMC-1.2 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvUNU0yODByIH7N MXe3NkBp MljabY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m NFzwT5AzOTJ2MkG4PS=>
C2 M1rVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362OlEuOTByMDDuUS=> NYrnOoc4PzJiaB?= NH\KcWVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV? Mn7uNlEzPDJzOEm=
CHP-212 M2SzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3c|EuOTJ3IH7N NET6NGUzPC1zMkCgbC=> M2PHSYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= M2rvUFIyOTZ7MkSy
IMR-32 NH3aT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPxNU0yOjVibl2= M3fWfFI1NTF{MDDo M3\UNIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= M3[y[FIyOTZ7MkSy
Kelly M{fScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\mUWoyNTF{NTDuUS=> MXGyOE0yOjBiaB?= NXHSc3JTcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> NIHsVlczOTF4OUK0Ni=>
SH-EP MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLlNU0yOjVibl2= Ml\6NlQuOTJyIHi= NIW1VFhqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l M3HxT|IyOTZ7MkSy
SH-SY5Y NHLq[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxMVEzPSCwTR?= NY\YU3NVOjRvMUKwJIg> MVvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n M3e5fVIyOTZ7MkSy
SK-N-AS NGjKV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnnNY91OS1zMkWgcm0> M2nLVVI1NTF{MDDo MX\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n MVmyNVE3QTJ2Mh?=
SK-N-BE MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRfFEuOTJ3IH7N NXv0OWhrOjRvMUKwJIg> NFjKd2xqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l MVeyNVE3QTJ2Mh?=
KG1 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjoSHNqOS9zMD:xNFAhdk1? MoC5O|IhcA>? M2KyXmROW09? Mn3abY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= Mn\HNVk1PTh|NUi=
U937 M4DiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxM|ExNzFyMDDuUS=> NX;LTIFvPzJiaB?= NH63fXlFVVOR NIfPfoFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l MYSxPVQ2QDN3OB?=
CAL62 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnRRYI3OC5zLUGwNEBvVQ>? MVG3NkBp NGq3VnZFVVOR NVmwc|N3TUN3ME2xMlQhdk1? M{jyeVE6OjJ|NUWz
OCUT-1 M3LNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\5WVhJOC5zLUGwNEBvVQ>? NWfS[INOPzJiaB?= Ml7nSG1UVw>? NF3YN2NGSzVyPUKuN{BvVQ>? M{TuN|E6OjJ|NUWz
8505C MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7FfIoxNjFvMUCwJI5O MWG3NkBp M1;NVmROW09? M3vQd2VEPTB;Mz6yJI5O Mli4NVkzOjN3NUO=
ACT-1 NXLmbZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfPO4cxNjFvMUCwJI5O NUm4VZZGPzJiaB?= M4LBU2ROW09? MYrFR|UxRTVwNDDuUS=> NI\CbXIyQTJ{M{W1Ny=>
SW1736 NUPzOo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13tSFAvOS1zMECgcm0> NX\BSJRnPzJiaB?= Mn3WSG1UVw>? MkXsSWM2OD13Lk[gcm0> M1fiS|E6OjJ|NUWz

... Click to View More Cell Line Experimental Data
In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing. 		15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3
CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia Myeloid Acute Boehringer Ingelheim October 2006 Phase 2
NCT00706498 Completed Prostatic Neoplasms Boehringer Ingelheim September 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

selleck catalog

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

  • Selective Plk Inhibitors

    GSK461364 : Plk1-selective, Ki=2.2 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

  • Calssic Plk Inhibitor

    Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products4

  • SBE 13 HCl New

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • Volasertib (BI 6727)

    Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

    Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID